Microbix Expands External Quality Assessment Program in Infectious Disease to Europe -- MEDICA - World Forum for Medicine


Microbix Biosystems

Microbix Expands External Quality Assessment Program in Infectious Disease to Europe

TORONTO, September 29, 2011 – Microbix Biosystems Inc. (TSX:MBX), a biologicals technology company that produces a large range of specialty infectious disease antigens in addition to developing its late-stage, multi-product pipeline, announced today that the Company is expanding its External Quality Assessment (EQA) product line in Europe.

Microbix, which for 25 years cultured over 20 different viruses and bacteria for its customers, launched a new line of viral antigen detection proficiency samples. Since 2009 these samples have been used by many of the leading proficiency testing providers in the United States in their CAP-approved proficiency testing programs.

Microbix is pleased to announce these samples are now available throughout Europe. These inactivated, ready to use samples meet all requirements of EQA programs across the European Union.

Samples are available for:

• Adenovirus
• Influenza A
• Influenza B
• Respiratory Syncytial virus
• Rotavirus
• Chlamydia

For a detailed description of these samples and our proficiency program please visit www.microbix.com/pt

To support these new product introductions, Microbix recently expanded its sales force in Europe by opening an office in Paris, France. The Company also has established distribution centers in China and India to ease overseas shipping costs for its customers. New distribution channels, along with a continually expanding and improving product line have made Microbix viral antigens the choice of nine of the world’s 10 largest diagnostic manufacturers.

At MEDICA 2011, Microbix will be exhibiting in Hall 3 as part of the Ontario, Canada pavilion and welcomes the media, visitors, and old friends. Inquiries from distributors and private label manufacturers are welcome.

About Microbix Biosystems

Microbix Biosystems Inc. specializes in the development of the most advanced vaccine production technology and markets virology and biological products worldwide. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Microbix supplies customers in the U.S., Europe, and Asia. Established in 1988, Microbix is headquartered in Toronto.
This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements.